This HTML5 document contains 46 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n11http://linked.opendata.cz/resource/domain/vavai/projekt/
n6http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n13http://linked.opendata.cz/resource/domain/vavai/subjekt/
n12http://linked.opendata.cz/ontology/domain/vavai/
n17http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F68378050%3A_____%2F12%3A00381624%21RIV13-GA0-68378050/
n16http://linked.opendata.cz/resource/domain/vavai/zamer/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n9http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n14http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n19http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n8http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n18http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n7http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n4http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F68378050%3A_____%2F12%3A00381624%21RIV13-GA0-68378050
rdf:type
skos:Concept n12:Vysledek
dcterms:description
Leishmaniasis remains a public health problem worldwide, affecting approximately 12 million people in 88 countries; 50 000 die of it each year. The disease is caused by Leishmania, obligate intracellular vector-borne parasites. In spite of its huge health impact on the populations in vast areas, leishmaniasis is one of the most neglected diseases. No safe and effective vaccine currently exists against any form of human leishmaniasis. The spectrum and efficacy of available antileishmanial drugs are also limited. First part of this review discusses the approaches used for the vaccination against leishmaniasis that are based on the pathogen and includes virulent or attenuated parasites, parasites of related nonpathogenic species, whole killed parasites, parasites' subunits, DNA vaccines, and vaccines based on the saliva or saliva components of transmitting phlebotomine vector. Second part describes parasite detection and quantification using microscopy assays, cell cultures, immunodetection, and DNA-based methods, and shows a progress in the development and application of these techniques. In the third part, first-line and alternative drugs used to treat leishmaniasis are characterized, and pre-clinical research of a range of natural and synthetic compounds studied for the leishmanicidal activity is described. The review also suggests that the application of novel strategies based on advances in genetics, genomics, advanced delivery systems, and high throughput screenings for leishmanicidal compounds would lead to improvement of prevention and treatment of this disease. Leishmaniasis remains a public health problem worldwide, affecting approximately 12 million people in 88 countries; 50 000 die of it each year. The disease is caused by Leishmania, obligate intracellular vector-borne parasites. In spite of its huge health impact on the populations in vast areas, leishmaniasis is one of the most neglected diseases. No safe and effective vaccine currently exists against any form of human leishmaniasis. The spectrum and efficacy of available antileishmanial drugs are also limited. First part of this review discusses the approaches used for the vaccination against leishmaniasis that are based on the pathogen and includes virulent or attenuated parasites, parasites of related nonpathogenic species, whole killed parasites, parasites' subunits, DNA vaccines, and vaccines based on the saliva or saliva components of transmitting phlebotomine vector. Second part describes parasite detection and quantification using microscopy assays, cell cultures, immunodetection, and DNA-based methods, and shows a progress in the development and application of these techniques. In the third part, first-line and alternative drugs used to treat leishmaniasis are characterized, and pre-clinical research of a range of natural and synthetic compounds studied for the leishmanicidal activity is described. The review also suggests that the application of novel strategies based on advances in genetics, genomics, advanced delivery systems, and high throughput screenings for leishmanicidal compounds would lead to improvement of prevention and treatment of this disease.
dcterms:title
Leishmaniasis: prevention, parasite detection and treatment Leishmaniasis: prevention, parasite detection and treatment
skos:prefLabel
Leishmaniasis: prevention, parasite detection and treatment Leishmaniasis: prevention, parasite detection and treatment
skos:notation
RIV/68378050:_____/12:00381624!RIV13-GA0-68378050
n12:predkladatel
n13:ico%3A68378050
n3:aktivita
n8:P n8:Z
n3:aktivity
P(GA310/08/1697), P(LC06009), Z(AV0Z50520514)
n3:cisloPeriodika
10
n3:dodaniDat
n4:2013
n3:domaciTvurceVysledku
n6:5279097 n6:8665869 n6:6111122
n3:druhVysledku
n7:J
n3:duvernostUdaju
n14:S
n3:entitaPredkladatele
n17:predkladatel
n3:idSjednocenehoVysledku
146785
n3:idVysledku
RIV/68378050:_____/12:00381624
n3:jazykVysledku
n19:eng
n3:klicovaSlova
tropical disease; kala-azar; preventive medicine; animal model
n3:klicoveSlovo
n9:preventive%20medicine n9:tropical%20disease n9:kala-azar n9:animal%20model
n3:kodStatuVydavatele
NL - Nizozemsko
n3:kontrolniKodProRIV
[CDB87F6D24FC]
n3:nazevZdroje
Current Medicinal Chemistry
n3:obor
n18:EB
n3:pocetDomacichTvurcuVysledku
3
n3:pocetTvurcuVysledku
3
n3:projekt
n11:GA310%2F08%2F1697 n11:LC06009
n3:rokUplatneniVysledku
n4:2012
n3:svazekPeriodika
19
n3:tvurceVysledku
Kobets, Tetyana Grekov, Igor Lipoldová, Marie
n3:wos
000302118600004
n3:zamer
n16:AV0Z50520514
s:issn
0929-8673
s:numberOfPages
32